Clinical calculator summary
Early-Stage Hodgkin Risk Calculator
Clinical calculator summary
Early-Stage Hodgkin Risk Calculator
A rule-based classifier for favorable versus unfavorable stage I-II classical Hodgkin lymphoma.
Evidence-based context for fast calculator use
- Purpose:
- Support risk-adapted early Hodgkin treatment discussion
- Population:
- Stage I-II classical Hodgkin lymphoma
- Factors:
- Mediastinal bulk, Nodal areas, ESR, B symptoms, Extranodal disease, Age
- Reference:
- GHSG, EORTC/LYSA, and NCCN early-stage Hodgkin risk definitions
Early-Stage Hodgkin Lymphoma Risk
Clinical Context & Background
Unfavorable if any selected-system unfavorable factor is present; otherwise favorable.Reference Data
| System | Unfavorable Factors Summarized |
|---|---|
| GHSG | Large mediastinal mass, extranodal disease, >2 nodal areas, or ESR >50 without B symptoms / >30 with B symptoms |
| EORTC/LYSA | Large mediastinal mass, age >=50, >=4 nodal areas, or ESR >50 without B symptoms / >30 with B symptoms |
| NCCN | Bulky mediastinal or >10 cm disease, B symptoms, ESR >50, or >3 disease sites |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use Early-Stage Hodgkin Lymphoma Risk when classify stage I-II classical Hodgkin lymphoma as favorable or unfavorable using GHSG, EORTC/LYSA, or NCCN-style risk factors.
- Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.
How To Interpret
- Interpret the displayed result using the calculator-specific formula and reference table, spanning GHSG through NCCN.
- A boundary result should prompt input verification and clinical review rather than false precision.
What To Do Next
- Confirm histology, stage, LDH reference range, extranodal disease, performance status, and treatment timing.
- Document the inputs, result, timing, and clinical context so the assessment can be reproduced.
Limitations
- Do not apply a lymphoma index to a different histology or relapse setting without validation.
- The result supports clinician judgment and does not independently determine treatment.
Validated Population
patients with the lymphoma subtype and treatment setting described by the model
How to apply this result
For a representative case, verify Risk definition, Bulky mediastinal disease or mass >10 cm?, Number of involved nodal areas/sites, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.
Popular Tools
Frequently Asked Questions
Why do GHSG, EORTC, and NCCN sometimes disagree?
The systems use overlapping but different cutoffs for nodal sites, bulky mediastinum, age, extranodal disease, B symptoms, and ESR. Use the system specified by the protocol or guideline being followed.
Does favorable risk mean no treatment is needed?
No. Favorable risk describes a lower-risk stage I-II group for risk-adapted therapy planning; treatment still depends on guideline context and PET response.
Evidence-based oncology decision support. Verify with clinical guidelines.